Search

The Drug Enforcement Administration is excusing Veterans Affairs' virtual care providers from participating in a federal telehealth controlled substance registry framework if the patient had a previous in-person visit.

The rule would establish a framework for a telehealth controlled substance registry and authorize three types of special registration. Some industry groups have voiced concerns for providers in their initial reactions to the proposed rule.

The third extension of pandemic-era telehealth flexibilities through the end of next year will give the agencies time to promulgate final regulations and providers time to comply, the agencies said.

Approximately 10% of all U.S. healthcare workers will divert opioids or other controlled substances from their workplace at some point in their career.1 Drug diversion, or the illegal distribution or abuse of prescription drugs, remains a top challenge at hospitals and health systems across the country, and is often undiscovered and underreported.2

Chris Harle, a longtime clinical informatics leader who has worked as a biomedical researcher at Regenstrief and a health policy professor at Indiana University's school of public health, will helm the IT and data innovations at Regenstrief Data Services.

From EHR optimization to AI-enabled CDS, big advancements are happening with biomedical informatics. Chris Harle, researcher at Regenstrief Institute and professor at Indiana University, discusses data science, provider experience, patient safety and more.

In what it's calling "one of the most ambitious initiatives in its 250-year history," NewYork-Presbyterian has launched a new $2 billion capital campaign that has advanced technologies and digital transformation as core goals.

Bipartisan lawmakers say a temporary extension isn't adequate, and they're concerned that the draft proposal is "misaligned with Congressional intent" with regard to a registry for the prescribing of controlled substances via telemedicine.

OpenAI's GPT-4 and Google's Gemini did not recommend opioid medication for one group over another – suggesting that artificial intelligence could help address clinician bias and improve fairness in treating pain.